Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,970.00
Bid: 1,970.00
Ask: 1,972.00
Change: -24.00 (-1.20%)
Spread: 2.00 (0.102%)
Open: 2,004.00
High: 2,004.00
Low: 1,966.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Fri, 06th Aug 2021 07:42

(Alliance News) - Stock trading in London is set for a subdued start on Friday, as traders slip into a wait-and-see mode ahead of the monthly US job report.

Investors are "going to remain on the edge" ahead of the print, said AvaTrade's Naeem Aslam.

"One particular factor that has damped the expectation for today's US NFP number is the US ADP number released earlier this week. The number missed the forecast significantly, and this should be considered an alarming sign for traders," he said.

Wednesday's ADP figure for July job creation disappointed at 330,000, well below both the 680,000 jobs added in June and consensus forecasts, according to FXStreet, of 695,000.

Friday's report, due at 1330 BST, is expected to show the US added 870,000 jobs in July, up from 850,000 in June.

In early UK company news, London Stock Exchange Group lifted its guidance for Refinitiv cost synergies after a good start to 2021, and Hikma raised its outlook for its Generics arm.

IG says futures indicate the FTSE 100 to open up 6.7 points, or 0.1%, at 7,127.30 on Friday. The index of large-caps closed down 3.43 points, or 0.1%, at 7,120.43 on Thursday.

The dollar was advancing ahead of the all-important US jobs figure.

Sterling was quoted at USD1.3921 early Friday, lower than USD1.3935 at the London equities close on Thursday.

The euro traded at USD1.1827 early Friday, soft on USD1.1843 late Thursday. Against the yen, the dollar rose to JPY109.82 versus JPY109.71.

Gold softened to USD1,800.59 an ounce early Friday from USD1,802.55 on Thursday.

In early UK company news, London Stock Exchange Group said it started the year well with cost savings from its integration of new acquisition Refinitiv running ahead of plan.

Revenue for the first half of 2021 jumped to GBP2.99 billion from GBP877 million a year ago, with pretax profit nearly doubling to GBP510 million from GBP262 million.

"LSEG has delivered a good financial performance in the first half of the year, reflecting revenue growth across all divisions," said Chief Executive David Schwimmer.

LSEG said the "favourable outlook" supports a 7% increase in its interim payout to 25.0 pence.

The firm added it progressed its integration of Refinitiv in the half-year, and its cost synergy programme is ahead of plan with GBP77 million realised in the period. As a result, it raised full-year run-rate cost synergy guidance to GBP125 million from GBP88 million.

LSEG finally completed its USD27 billion acquisition for financial market data and infrastructure provider Refinitiv in January after first making its interest clear back in July 2019.

"Revenue synergies have had a good start, at GBP4 million run-rate achieved, though will take time to build while requiring upfront investment already included within our stated investment expectations," LSEG said.

Hikma Pharmaceuticals reported interim profit growth and lifted the full-year outlook for its Generics division.

Revenue for the first half of the year rose 7% to USD1.22 billion as all three divisions - Generics, Global Injectables and Branded - performed well. Pretax profit rose 16% to USD319 million from USD274 million.

Generics delivered "strong" revenue growth and significant margin improvement, while Global Injectables saw modest sales growth after a stellar showing a year ago. Branded achieved double-digit revenue growth and improved margins.

It now expects Generics revenue in a range of USD810 million to USD830 million for 2021 as a whole, up from previous guidance of USD770 million to USD810 million to reflect a strong performance from recently launched products. Full-year forecasts for the other two units were retained.

Sanne Group confirmed that, after Apex's takeover interest, it is still in merger talks with Cinven and requested a 'put up or shut up' deadline extension.

"Cinven is considering its options and continues to work closely with Sanne regarding a possible offer," said Sanne, a London-based provider of alternative asset and corporate services.

Cinven now has until August 30 - the same deadline as rival suitor Apex - to either announce a firm offer for Sanne or walk away.

In the US on Thursday, Wall Street ended in the green, with the Dow Jones Industrial Average up 0.8%, the S&P 500 up 0.4%, and the Nasdaq Composite up 0.8%.

US President Joe Biden's plan for a USD1.2 trillion investment in US infrastructure will face a key step in the Senate on Saturday to come to the floor for a final vote, before heading to the House of Representatives.

After spending hours on Thursday in talks to try to find consensus for a vote on Saturday, Senate Democratic Majority Leader Chuck Schumer finally announced late in the day that he was homing in on his goal.

"I believe we're very close to an agreement and see no reason why we can't complete this important bipartisan bill. So I urge both sides to continue working diligently to make it happen," he said.

In Asia on Friday, the Japanese Nikkei 225 index ended up 0.3%. In China, the Shanghai Composite was down 0.4%, while the Hang Seng index in Hong Kong was flat. The S&P/ASX 200 in Sydney ended up 0.4%.

Brent oil was trading at USD71.64 a barrel early Friday, higher than USD70.85 late Thursday.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Aug 2021 16:04

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
6 Aug 2021 17:06

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

Read more
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.